Loading...

Pear Therapeutics, Inc.

PEAR•NASDAQ
HealthcareMedical - Healthcare Information Services
$0.03
$0.00(0.00%)

Pear Therapeutics, Inc. (PEAR) Stock Overview

Explore Pear Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for PEARStats details for PEAR are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for PEARAnalyst Recommendations details for PEAR are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.

CEO

Mr. Christopher D. T. Guiffre J.D., M.B.A., MBA

Employees

200

Headquarters

200 State Street, Boston, MA

Founded

2021

Frequently Asked Questions